{
  "abstract": "The management of persons with an initial clinical demyelinating event (PwICDE) is controversial. Frequently, patients with ICDE are often treated with an Multiple Sclerosis (MS) disease-modifying therapy (DMT), while in others, a “wait-and-see” approach is followed. Even in PwICDE who are prescribed a DMT, there are significant barriers to initiation of therapy. A reliable biomarker that can predict when it is safe to monitor patients rather than start a DMT would be highly beneficial. The CXCL13 index (I CXCL13 ), which measures the intrathecal production of CXCL13, a key chemokine for trafficking B cells and follicular helper T(Tfh) cells, is such a biomarker. In this study, low I CXCL13 is shown to predict the safety of remaining off DMTs.",
  "abstract_shown": true,
  "affiliations": [
    "Dartmouth College",
    "Dartmouth-Hitchcock Medical Center"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Andrew R. Pachner"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Steven C. Pike"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Francesca Gilli"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ag244ayv42qm0.bib",
  "cited_by": 0,
  "doi": "10.3389/fneur.2026.1823278",
  "fulltext_url": null,
  "id": "ag244ayv42qm0",
  "issns": [
    "1664-2295"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fneur.2026.1823278/full",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-05",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/ag244ayv42qm0.ris",
  "sources": [
    {
      "first_seen": "2026-11-05T12:21:27Z",
      "native_id": "10.3389/fneur.2026.1823278",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fneur.2026.1823278/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:1664-2295",
      "subfield": "neurology"
    }
  ],
  "title": "Not every patient with an initial clinical demyelinating event needs to be treated: a low CXCL13 index at the time of the ICDE has prognostic value for the absence of later activity",
  "title_text": "Not every patient with an initial clinical demyelinating event needs to be treated: a low CXCL13 index at the time of the ICDE has prognostic value for the absence of later activity",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T00:21:25Z",
  "url": "https://research.draconitic.com/paper/ag244ayv42qm0",
  "venue": "Frontiers in Neurology",
  "versions": []
}